Title:
ＣＬＥＣ１２Ａ発現癌を標的にするための組成物および方法
Document Type and Number:
Japanese Patent JP7315244
Kind Code:
B2
Abstract:
Disclosed are compositions and methods for targeted treatment of CLEC12A-expressing cancers. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used with adoptive cell transfer to target and kill CLEC12A-expressing cancers. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a CLEC12A-expressing cancer that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs. Also disclosed are multivalent antibodies are disclosed that are able to engage T-cells to destroy CLEC12A-expressing malignant cells.
More Like This:
Inventors:
Davila, Marco El.
Application Number:
JP2020537630A
Publication Date:
July 26, 2023
Filing Date:
January 08, 2019
Export Citation:
Assignee:
H.Remofit Cancer Center and Research Institute Incorporated
International Classes:
C12N15/62; A61K35/17; A61K38/17; A61K39/395; A61K45/00; A61P7/00; A61P35/00; A61P35/02; C07K14/705; C07K16/28; C07K19/00; C12N1/15; C12N1/19; C12N1/21; C12N5/078; C12N5/0781; C12N5/0783; C12N5/10; C12N15/12; C12N15/13; C12N15/63
Domestic Patent References:
| JP2017522879A |
Other References:
CLAUDIA ROSSIG; ET AL,EPSTEIN-BARR VIRUS-SPECIFIC HUMAN T LYMPHOCYTES EXPRESSING ANTITUMOR CHIMERIC T-CELL RECEPTORS: POTENTIAL FOR IMPROVED IMMUNOTHERAPY,BLOOD,2002年03月15日,VOL.99,NO.6,PAGE(S):2009-2016,https://doi.org/10.1182/blood.V99.6.2009
Attorney, Agent or Firm:
Patent Attorney Corporation Hiroe Associates Patent Office